ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Shattuck Labs Inc

Shattuck Labs Inc (STTK)

1.035
-0.075
( -6.76% )
Updated: 11:27:38

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.035
Bid
1.03
Ask
1.04
Volume
76,659
1.03 Day's Range 1.12
1.03 52 Week Range 11.76
Market Cap
Previous Close
1.11
Open
1.11
Last Trade
1
@
1.03
Last Trade Time
11:34:08
Financial Volume
$ 80,594
VWAP
1.0513
Average Volume (3m)
599,600
Shares Outstanding
47,739,708
Dividend Yield
-
PE Ratio
-0.57
Earnings Per Share (EPS)
-1.83
Revenue
1.66M
Net Profit
-87.3M

About Shattuck Labs Inc

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restor... Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-
Shattuck Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STTK. The last closing price for Shattuck Labs was $1.11. Over the last year, Shattuck Labs shares have traded in a share price range of $ 1.03 to $ 11.76.

Shattuck Labs currently has 47,739,708 shares outstanding. The market capitalization of Shattuck Labs is $52.99 million. Shattuck Labs has a price to earnings ratio (PE ratio) of -0.57.

STTK Latest News

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

 – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 –  – Cash balance of approximately $90M as of September 30...

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest...

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes...

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.175-14.46280991741.211.561.033127551.23991145CS
4-0.265-20.38461538461.31.561.033328061.24851917CS
12-2.435-70.17291066283.473.951.035996001.69667852CS
26-6.485-86.23670212777.527.8251.034877702.8822525CS
52-1.185-53.37837837842.2211.761.037597105.38304878CS
156-8.405-89.03601694929.4411.761.033316335.25602462CS
260-17.575-94.438473938718.6160.51621.032961679.4032396CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 2.0002
(104.10%)
109.68M
CRNCCerence Inc
$ 4.83
(71.28%)
34.81M
IBGInnovation Beverage Group Limited
$ 1.135
(43.45%)
8.84M
QUBTQuantum Computing Inc
$ 5.0514
(37.27%)
90.59M
SPAISafe Pro Group Inc
$ 4.2701
(33.44%)
38.86M
GLXGGalaxy Payroll Group Ltd
$ 1.68
(-57.03%)
892.74k
PYXSPyxis Oncology Inc
$ 2.07
(-45.81%)
9.55M
KURAKura Oncology Inc
$ 10.08
(-36.64%)
7.96M
BLRXBioLineRx Ltd
$ 0.3545
(-34.98%)
6.17M
SHOTWSafety Shot Inc
$ 0.1001
(-33.27%)
2.5k
CDTConduit Pharmaceuticals Inc
$ 0.111001
(20.26%)
496.04M
NVDANVIDIA Corporation
$ 145.1021
(-0.54%)
205.78M
AKTSAkoustis Technologies Inc
$ 0.1003
(15.15%)
184.24M
ELABElevai Labs Inc
$ 0.0202
(-5.61%)
174.72M
WORXSCWorx Corporation
$ 2.0002
(104.10%)
108.78M

STTK Discussion

View Posts
TrendTrade2016 TrendTrade2016 1 month ago
STTK COMING OFF BOTTOM
👍️0
glenn1919 glenn1919 1 month ago
STTK............................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
STTK under $4
👍️0
PonkenPlonken PonkenPlonken 6 months ago
absolutely revolutionary data in HR MDS... compare to SOC!!! HMAs show a ORR 30%, CR 10-20%
(also beats venetoclax + HMA in TP53m AML)

Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% –

– Observed 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral blood count improvement, these patients continue on treatment
👍️0
Monksdream Monksdream 7 months ago
STTK new 52 week high
👍️0
Monksdream Monksdream 10 months ago
STTK new 52 week high
👍️0
Monksdream Monksdream 11 months ago
STTK new 52 week low
👍️0
tbonaces80 tbonaces80 11 months ago
Takeda gonna tender on next trial fast track
👍️0
tbonaces80 tbonaces80 11 months ago
load it-going to 10+
👍️0
subslover subslover 11 months ago
No fooling? So you say a 1.75% profit for a two-hour trade is a bad trade?
👍️0
tbonaces80 tbonaces80 11 months ago
Bad trade
👍️0
subslover subslover 11 months ago
Ok. I got out of this POS this morning at $5.00, got lucky is all
👍️0
TheFinalCD TheFinalCD 11 months ago
@ 4.29 I was just looking for a move under $4 and it did

small gain, but I didnt know how many borrows I could get if it went against me

sometimes I go short, and get upside down and cant average up, because broker all of a sudden has NO available shares to short= your stuck

so thats why I dont short much
👍️0
subslover subslover 11 months ago
What price did you short?tia
👍️0
TheFinalCD TheFinalCD 11 months ago
I shorted it... Its just Phase 1

AI bot hyper extended the POP

I used to chase these Pase 1 rallys, lost lots of money doing so

some of my biggest losses ever

Phase 1 Gap & Traps
👍️0
subslover subslover 11 months ago
Did you see this open? $7.28! then immediately dropped down to $2.50 omg. I'm in at $3.00 just hoping for the best. Worth a shot
👍️0
TheFinalCD TheFinalCD 11 months ago
https://twitter.com/TigerLineTrades/status/1734900423301988796
👍️0
subslover subslover 11 months ago
$TSOI's new Introducing the ALScell™, also known as the JadiCell™ – Now, these ALScells are not your run-of-the-mill mesenchymal stem cells; they're basically the overachievers of the cellular world. These ALScells have it all – enhanced growth factor production, like they've been hitting the gym and drinking protein shakes on a regular basis. They can secrete exosomes , outshining their stem cell peers who are still trying to figure out how to tie their cellular shoelaces.

But wait, there's more! These ALScells are not just content with being academically gifted; they've got some serious street smarts too. Superior angiogenic and neurogenic abilities mean they're like the cool kids who not only excel in science class but also throw legendary parties in the cellular neighborhood.

And guess what? Exosomes are not just a fancy word; they're the VIP pass to the cure of many cancers. It's like the ALScells are hosting the party, and exosomes are the invitations that cancer cells can't resist.

So, say hello to the ALScell™ – the cellular superhero ready to save the day, one enhanced growth factor at a time, and unlocking cures like a boss!
Bullish
BULLISH
👍️0
Awl416 Awl416 11 months ago
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pati
👍️0
Monksdream Monksdream 1 year ago
STTK under $2
👍️0

Your Recent History

Delayed Upgrade Clock